Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 28Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 22Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Carcinoma, Non-Small-Cell Lung 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Glioblastoma 13Leukemia, Lymphocytic, Chronic, B-Cell 12Brain Neoplasms 12Recurrence 11Neuroblastoma 11Myelodysplastic Syndromes 11Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Burkitt Lymphoma 11Neoplasms 10Sezary Syndrome 9Congenital Abnormalities 9Prostatic Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Squamous Cell Carcinoma of Head and Neck 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms, Plasma Cell 7

Interventions

Surveys and Questionnaires 5pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2temsirolimus 1satraplatin 1ridaforolimus 1ixazomib 1X-Rays 1Videotape Recording 1Valproic Acid 1Trastuzumab 1Sugars 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Cancers × Vorinostat × Clear all
NCT02042989 2022-07-11

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
68 enrolled

Advanced Cancers

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡